版本:
中国

Daiichi Sankyo Co Ltd (4568.T)

4568.T ( 东京证券交易所 )

3,758JPY
20 Apr 2018
涨跌 (%)

¥34 (+0.91%)
收盘
¥3,724
开盘
¥3,723
当日最高
¥3,804
当日最低
¥3,720
成交量
1,253,900
平均成交量
2,391,456
52 周最高
¥4,241
52 周最低
¥2,284

Chart for

概况

DAIICHI SANKYO COMPANY, LIMITED是一家主要从事药品生产和销售业务的日本控股公司。该公司于日本、美国、欧洲、中国及巴西市场从事药物研发、制造及销售,以及提供药物生产中间体及基本原料。截至2014年3月31日,该公司拥有100家子公司和4家联营公司。

概况

Beta: 0.84
市值(百万): ¥2,664,465.00
已发行股本(百万): 709.01
股息: 35.00
股息收益率 (%): 1.86

财务指标

  4568.T Industry Sector
P/E (TTM): 65.90 31.01 33.60
EPS (TTM): 57.03 -- --
ROI: 1.99 13.60 13.19
ROE: 3.12 15.26 15.00

BRIEF-Vaxart Announces $5 Mln Inavir Revenue Milestone

* VAXART - NOTIFIED BY DAIICHI SANKYO CO THAT SALES OF INAVIR EXCEEDED ¥20 BILLION IN FISCAL YEAR 2017, TRIGGERING A $5 MILLION MILESTONE PAYMENT TO CO 全文
04/20 20:06

BRIEF-‍Daiichi Sankyo And Darwinhealth Enter Exclusive Research Collaboration For Novel Cancer Target Initiative​

* ‍DAIICHI SANKYO AND DARWINHEALTH ENTER EXCLUSIVE RESEARCH COLLABORATION FOR NOVEL CANCER TARGET INITIATIVE​ 全文
04/04 20:11

BRIEF-Daiichi Sankyo Initiates Phase 2 Study Of DS-8201

* DAIICHI SANKYO INITIATES PHASE 2 STUDY OF DS-8201 IN PATIENTS WITH HER2-EXPRESSING ADVANCED COLORECTAL CANCER Source text for Eikon: Further company coverage: 全文
03/07 21:15

BRIEF-Daiichi Sankyo Aligns U.S. Commercial Operations To Current Portfolio, Upcoming Cancer Pipeline

* DAIICHI SANKYO, INC. ALIGNS U.S. COMMERCIAL OPERATIONS TO CURRENT PORTFOLIO AND UPCOMING CANCER PIPELINE 全文
03/01 04:02

BRIEF-Daiichi Sankyo Initiates Phase 1 Study Of DS-1062 In Patients With Advanced Non-Small Cell Lung Cancer

* DAIICHI SANKYO INITIATES PHASE 1 STUDY OF DS-1062 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER Source text for Eikon: Further company coverage: 全文
02/22 21:12

BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer

* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage: 全文
12/13 05:44

BRIEF-Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​

* ‍Daiichi Sankyo announces enliven Phase 3 study of Pexidartinib met primary endpoint in Tenosynovial giant cell tumor​ Source text for Eikon: Further company coverage: 全文
10/31 12:04

收益 vs. 预测